Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

NCT06603142 is registered in ClinicalTrials.gov with Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd as lead sponsor.

NCT NCT06603142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06603142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia
Lead sponsor
Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
April 22, 2024
Completion date
April 30, 2026
Enrollment
636 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia, primary gout